PTC Therapeutics (PTCT) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

PTC Therapeutics (PTCT) overview

PTC Therapeutics (PTCT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 1,731m and operating profit of USD 867m; the year-end share price was 75.96 USD and market capitalisation was USD 6,189m. PTC Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get PTC Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD -205mFY 2025
Share price75.96 USDFY 2025 year end
RevenueUSD 1,731mFY 2025
Operating profitUSD 867mFY 2025
Net earningsUSD 683mFY 2025
Market capitalisationUSD 6,189mFY 2025 year end

About PTC Therapeutics

PTC Therapeutics is a global biopharmaceutical company that discovers, develops, and commercializes medicines for rare disorders in children and adults. Its portfolio includes treatments for phenylketonuria, Duchenne muscular dystrophy, AADC deficiency, and other rare conditions, alongside product candidates in development. The company’s therapeutic focus includes neurology and metabolism. It also holds commercialization rights for certain rare disease medicines in Latin America and the Caribbean.

Generate the PTC Therapeutics report

PTC Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for PTC Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on PTC Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.